TEST BANK
Goodman and Gilman's The
Pharmacological Basis of Therapeutics
14th Edition
Author(s)Laurence Brunton; Bjorn Knollmann
Print ISBN: 9781264258079
,Question 1
A research team identifies a plant-derived compound that reduces
proliferation of cancer cells in an initial biological assay. The compound
has a measurable effect but is chemically unstable and difficult to
formulate. Which step is most appropriate before extensive clinical
development?
,A. Immediately begin Phase III clinical trials
B. Optimize the compound as a lead through medicinal chemistry and
pharmacological evaluation
C. Discard the compound because natural products are unsuitable as
drug candidates
D. Replace the biological assay with a toxicity study only
Correct Answer:
B. Optimize the compound as a lead through medicinal chemistry and
pharmacological evaluation
Rationale:
B is correct because discovery often begins with identification of a
biologically active molecule, followed by lead optimization to improve
properties such as potency, selectivity, stability, and developability. A is
incorrect because extensive preclinical optimization is necessary before
large-scale clinical testing. C is incorrect because natural products can
provide valuable starting points for drug discovery. D is incorrect
because toxicity assessment is important but does not replace the
broader process of improving the lead compound and characterizing its
pharmacological properties.
Question 2
Which characteristic most directly distinguishes a lead compound from
an initial hit identified during drug discovery?
A. A lead has already demonstrated therapeutic efficacy in humans
B. A lead has undergone sufficient optimization to justify further
development
C. A lead is always derived from a synthetic chemical library
D. A lead must have no measurable adverse effects
, Correct Answer:
B. A lead has undergone sufficient optimization to justify further
development
Rationale:
B is correct because a lead is a promising starting point for further
optimization and development based on biological activity and chemical
properties. A is incorrect because human efficacy is established later in
development. C is incorrect because leads can originate from natural
products, synthetic compounds, or other discovery approaches. D is
incorrect because early leads may have undesirable effects that can
potentially be modified through optimization.
Question 3
A medicinal chemist modifies several substituents on a biologically
active molecule and observes that one modification markedly increases
potency while another decreases potency. What type of information is
primarily being generated?
A. Structure-activity relationship information
B. Epidemiological information
C. Clinical pharmacokinetic information
D. Postmarketing surveillance information
Correct Answer:
A. Structure-activity relationship information
Rationale:
A is correct because structure-activity relationship analysis examines
how chemical changes influence biological activity, helping identify
molecular features associated with potency or selectivity. B concerns
Goodman and Gilman's The
Pharmacological Basis of Therapeutics
14th Edition
Author(s)Laurence Brunton; Bjorn Knollmann
Print ISBN: 9781264258079
,Question 1
A research team identifies a plant-derived compound that reduces
proliferation of cancer cells in an initial biological assay. The compound
has a measurable effect but is chemically unstable and difficult to
formulate. Which step is most appropriate before extensive clinical
development?
,A. Immediately begin Phase III clinical trials
B. Optimize the compound as a lead through medicinal chemistry and
pharmacological evaluation
C. Discard the compound because natural products are unsuitable as
drug candidates
D. Replace the biological assay with a toxicity study only
Correct Answer:
B. Optimize the compound as a lead through medicinal chemistry and
pharmacological evaluation
Rationale:
B is correct because discovery often begins with identification of a
biologically active molecule, followed by lead optimization to improve
properties such as potency, selectivity, stability, and developability. A is
incorrect because extensive preclinical optimization is necessary before
large-scale clinical testing. C is incorrect because natural products can
provide valuable starting points for drug discovery. D is incorrect
because toxicity assessment is important but does not replace the
broader process of improving the lead compound and characterizing its
pharmacological properties.
Question 2
Which characteristic most directly distinguishes a lead compound from
an initial hit identified during drug discovery?
A. A lead has already demonstrated therapeutic efficacy in humans
B. A lead has undergone sufficient optimization to justify further
development
C. A lead is always derived from a synthetic chemical library
D. A lead must have no measurable adverse effects
, Correct Answer:
B. A lead has undergone sufficient optimization to justify further
development
Rationale:
B is correct because a lead is a promising starting point for further
optimization and development based on biological activity and chemical
properties. A is incorrect because human efficacy is established later in
development. C is incorrect because leads can originate from natural
products, synthetic compounds, or other discovery approaches. D is
incorrect because early leads may have undesirable effects that can
potentially be modified through optimization.
Question 3
A medicinal chemist modifies several substituents on a biologically
active molecule and observes that one modification markedly increases
potency while another decreases potency. What type of information is
primarily being generated?
A. Structure-activity relationship information
B. Epidemiological information
C. Clinical pharmacokinetic information
D. Postmarketing surveillance information
Correct Answer:
A. Structure-activity relationship information
Rationale:
A is correct because structure-activity relationship analysis examines
how chemical changes influence biological activity, helping identify
molecular features associated with potency or selectivity. B concerns
